JACC. Case reports · 2025
Pregnancy and Delivery Care for a Patient With a HeartMate 3.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jones Sara I, Acuff Heather, Best Ryan, Gee Yen-Yen, Snow Sarah C, Agarwal Richa, Rosario Karen Flores, Gilner Jennifer B, Federspiel Jerome J, Meng Marie-Louise
Аннотация
BACKGROUND: The limited available data on pregnancies among patients with left ventricular assist devices (LVADs) in situ shows elevated rates of maternal and fetal/neonatal morbidity and mortality. The first fully magnetically levitated device providing centrifugal continuous flow, HeartMate 3 (HM3, Abbott), is the only LVAD available in the United States since 2018 and has fewer adverse patient outcomes compared with previous devices.
CASE SUMMARY: A 32-year-old G5P2113 woman became pregnant 19 months after destination-therapy HM3 LVAD placement. Uncomplicated antepartum care and a cesarean delivery at 34 weeks under neuraxial anesthesia was facilitated by our institution's pregnancy heart team.
DISCUSSION: This represents the second reported HM3-supported pregnancy resulting in a live birth. Various barriers to care guided a shared anticoagulation plan, and no hemorrhagic or thrombotic complications occurred. Our intrapartum monitoring strategy facilitated a patient-centered delivery and postpartum experience while maintaining excellent patient safety.
CASE SUMMARY: A 32-year-old G5P2113 woman became pregnant 19 months after destination-therapy HM3 LVAD placement. Uncomplicated antepartum care and a cesarean delivery at 34 weeks under neuraxial anesthesia was facilitated by our institution's pregnancy heart team.
DISCUSSION: This represents the second reported HM3-supported pregnancy resulting in a live birth. Various barriers to care guided a shared anticoagulation plan, and no hemorrhagic or thrombotic complications occurred. Our intrapartum monitoring strategy facilitated a patient-centered delivery and postpartum experience while maintaining excellent patient safety.